Navigation Links
BIO 2006 aftermath and a taste of bio-generics

One of my favorite Rolling Stones' albums, not necessarily their best mind you, growing up was "Aftermath", an appropriate label for this period following all the intensity and excitement of BIO 2006- Chicago.

As BIO 2006 - Chicago is still fresh in our minds, I was going to give my take on the outcome, but so many others have already done so that I will wai......

Full article >>> addressed the worldwide generic pharmaceutical market. The reality is that the generic market differs widely around the world due to the role of patents, physician compensation, patient insurance reimbursement, and other factors in each country.

In places like India where patents are just beginning to take effect, prices are among the lowest in the world but will gradually rise. On the ot......

Full article >>> r patents expire (or have already expired some time ago), and a number of companies have lined up to both produce and launch these products in Europe and the United States, but the regulatory authorities in both regions have put the brakes on any approval process.

Traditionally, generics have been able to get FDA approval through a relatively simple Abbreviated New Drug Approval (ANDA) pr......

Full article >>> CompanyActive DrugPatent Expiration DateGlobal Sales(2002)HumulinEli LillyHuman insulin2001$1.0 billionIntron ASchering-PloughAlpha-interferon2002$2.5 billionProcritAmgen/J&Jerythropoietin<......

Full article >>> as been incredible jockeying for worldwide position in the generic market by several major players:

1. Teva Pharmaceuticals - Headquartered outside of Tel Aviz, Israel, ratcheted up its worldwide presence by the acquisition of fellow generic company IVAX last year and Sicor the year before.

2. Sandoz Pharmaceuticals (a division of pharmaceutical mega-player Novartis......

Full article >>> -Hetero Drugs-Hikal--IPCA Labs-Jal Limited--Krebs Biochemicals--Lupin-Malladi Drugs--......

Full article >>> you know that this is heating up, Sandoz filed a lawsuit against the FDA in September, 2005 regarding non-approval of its human growth hormone product.

The issue the FDA is grappling with is a need to show greater safety with these products requiring companies to do more clinical trials for bio-generics. It appears that a physician prescription will also be coupled with dispensing of the......

Full article >>> member of the Illinois Biotechnology Industry Organization. He can be reached at rosenmichaels@aol.com

The opinions expressed herein or statements made in the above column are solely those of the author and do not necessarily reflect the views of The Wisconsin Technology Network, LLC. (WTN). WTN, LLC, accepts n......

Full article >>>
'"/>

Source:wistechnology.com By Michael Rosen 04/23/06


Related biology technology :

1. June 30 is deadline to claim up to $223.9M in Microsoft settlement
2. Wisconsin firms wont rush to adopt Microsoft Vista
3. Microsoft to distribute $224M as part of settlement
4. Berbee wins two Microsoft awards
5. How Intuit competes with Microsoft, IRS
6. Oracle out, Microsoft in for state e-mail project
7. Microsoft gives software to Milwaukee education non-profit
8. Sonic Foundry earns respect from Microsoft
9. Berbee designated a Microsoft Small Business Specialist
10. Wisconsin Supreme Court rules against Microsoft
11. Inacom named Microsofts favorite learning solutions partner of the year
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2017)... , Feb 22, 2017 ... of the "Global Biological Crop Protection (Bio-Pesticide) Market-By Type, By ... (2016-2021)" report to their offering. ... Global Biological Crop Protection Market is forecasted ... The strong growth in biopesticide or biological crop protection market ...
(Date:2/22/2017)... Zurich, Switzerland (PRWEB) , ... February 22, 2017 ... ... Ltd ., announced the addition of Tom Perkins as European director. Operating from ... consulting experience to Pennside. , Perkins joins Pennside after more than a ...
(Date:2/21/2017)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: ... months ended December 31, 2016. SQI is ... company that develops and commercializes proprietary technologies and products for ... ... milestones achieved in fiscal 2016," said Andrew Morris , ...
(Date:2/21/2017)... ... February 21, 2017 , ... Cancer diagnostics workflow solution provider ... executive team to lead the development and commercialization of its Cancer Information Data ... diagnosis and treatment of cancer. The CIDT addresses the need for curated and ...
Breaking Biology Technology:
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 ... growing at a compound annual growth rate (CAGR) of 24.0% ... global markets for synthetic biology. - Analyses of global market ... of compound annual growth rates (CAGRs) through 2021. - Coverage ...
(Date:2/8/2017)... Report Highlights The global biosurgery ... billion in 2016 at a compound annual growth rate ... Includes - An overview of the global market for ... from 2015 and 2016, and projections of compound annual ... market on the basis of product type, source, application, ...
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
Breaking Biology News(10 mins):